期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型非典型抗精神病药:伊洛哌酮 被引量：2

A new atypical antipsychotic drug:iloperidone
原文传递
导出
摘要 伊洛哌酮为新型非典型抗精神病药,是多巴胺D2受体和5-HT受体拮抗药,能有效治疗精神分裂症。其常见的不良反应有头晕、口干、直立性低血压、体重增加等。本文对伊洛哌酮的药理学、药动学、临床评价、药物相互作用和安全性等进行综述。 Iloperidone,a new atypical antipsychotic drug,is indicated for the treatment of patients with schizophrenia acting as a serotonin/dopamine receptor antagonist.The most common adverse reactions of iloperidone are dizziness,dry mouth,orthostatic hypotension,and weight gain.The pharmacology,pharmacokinetics,clinical evaluation,drug interactions,and safety of iloperidone are reviewed in this paper.
作者 王来海 张红星 张瑞岭
机构地区 新乡医学院第二附属医院
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2010年第9期716-718,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 伊洛哌酮 受体 多巴胺 受体 血清素 非典型抗精神病药 药物评价 iloperidone receptors dopamine receptors serotonin atypical antipsychotic drug drug evaluation
分类号 R971.4 [医药卫生—药品]
  • 相关文献

参考文献13

  • 1CACCIA S, PASINA L, NOBILI A. New atypical antipsychotics for schizophrenia: iloperidone[J]. Drug Des Devel Ther, 2010, 18(4) : 33-48.
  • 2CITROME L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second- generation antipsychotic[J]. Int J Clin Pract, 2009, 63 (8): 1237 - 1248.
  • 3CUTLER AJ. Iloperidone: a new option for the treatment of schizophrenia[J]. Expert Rev Neurother, 2009, 9(12): 1727- 1741.
  • 4MARINO J, CABALLERO J. Iloperidone for the treatment of schizophrenia[J]. Ann Pharmacother, 2010, 44(5): 863-870.
  • 5BISHARA D, TAYLOR. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability[J]. Drugs, 2008, 68 (16) : 2269-2292.
  • 6CITROME L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commereialised second- generation antipsychntic [J]. Int J Clin Pract, 2009, 3 (8): 1237-1248.
  • 7ALBERS LJ, MUSENGA A, RAGGI MA. Iloperidone: a new benzisoxazole atypical andpsychotic drug. Is it novel enough to impact the crowded atypical antipsyehatie market? [J]. Expert Opin Investig Drugs, 2008, 17( 1 ) : 61-75.
  • 8KANE JM, LAURIELLO J, LASKA E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia[J]. J Clin Psychopharmacol, 2008, 28 (2 Suppl 1) : S29-S35.
  • 9CUTLER AJ, KALALI AH, WEIDEN PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia [J]. J Clin Psychopharmacol, 2008, 28(2 Suppl 1): S20-S28.
  • 10POTKIN SG, LITMAN RE, TORRES R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies[J]. J Clin Psychopharmacol, 2008, 28(2 Suppl 1) : S4-S11.

同被引文献19

  • 1CITROME L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics[J]. Postgrad Med, 2011, 123(2): 153-162.
  • 2MEYER JM, LOEBEL AD, SCHWEIZER E. Lurasidone: a new drug in development for schizophrenia [J]. Expert Opin Investig Drugs, 2009, 18(11): 1715-1726.
  • 3CITROME L. Lurasidone for schizophrenia: a review of the effi- cacy and safety profile for this newly approved second-generation antipsychotic [J]. Int J Clin Pract, 2011, 65 (2): 189-210.
  • 4CITROME L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic [J]. Clin Schizophr Relat Psy- choses, 2011, 4(4): 251-257.
  • 5ISHIYAMA T, TOKUDA K, ISHIBASHI T, et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK- 801-induced impairment of learning and memory in the rat passive-avoidance test[J]. Eur J Phannacol, 2007, 572 (2-3): 160-170.
  • 6ENOMOTO T, ISHIBASHI T, TOKUDA K, et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-ann maze tests in rats [J]. Behav Brain Res. 2008. 186(2) : 197-207.
  • 7HORISAWA T, ISHIBASHI T, NISH1KAWA I-I, et al. Theeffects of blK-8Ol-induced impaita~lent of learning and memory in the passi~,e a'~oidance aud Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone[J]. Behav Brain Res, 2011, 220 (1): 83-90.
  • 8ISHIBASHI T, HORISAWA T, TOKUDA K, et ol. Phar- macological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptaminc 7 (5-HT7) and 5-HT1A receptor activitv[J].J Pharmacol Ext~ Ther, 2010, 334(1 ): 171-181.
  • 9NEWMAN-TANCREDI A. The importance of 5-HT1A receptoragonism in antipsychotic drug action: rationale and perspec- tives[J]. Curt" Opin lnvestlg Drugs, 2010, 11 (7) : 802-812.
  • 10NAKAMURA M, OGASA M, GUARINO J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo- controlled trial[J]. J Clin Psychiatry, 2009, 70(6) : 829-836.

引证文献2

中国新药与临床杂志
2010年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部